These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32469065)

  • 21. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
    Taoka K; Okoshi Y; Sakamoto N; Takano S; Matsumura A; Hasegawa Y; Chiba S
    Int J Hematol; 2010 Nov; 92(4):617-23. PubMed ID: 20967518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
    Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
    Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.
    Aoki H; Ogura R; Tsukamoto Y; Okada M; Natsumeda M; Isogawa M; Yoshida S; Fujii Y
    Neurol Med Chir (Tokyo); 2013; 53(11):797-804. PubMed ID: 24162244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience.
    Yoshida M; Kato T; Hiu T; Imaizumi Y; Morimoto S; Niino D; Yamaguchi S; Baba S; Ujifuku K; Yoshida K; Matsuo A; Morofuji Y; Izumo T; Okano S; Miyazaki Y; Matsuo T
    Int J Hematol; 2023 Sep; 118(3):333-339. PubMed ID: 37393325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
    Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
    Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].
    Okamoto S; Tanaka M; Goto T; Nakashima M; Nagura E
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2109-2112. PubMed ID: 29361628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
    Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
    Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
    Faivre G; Butler MJ; Le I; Brenner A
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.
    Cheah CY; Milgrom S; Chihara D; Gombos DS; Pinnix CC; Dabaja BS; Fowler NH
    Neuro Oncol; 2016 Apr; 18(4):575-81. PubMed ID: 26487691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment for primary CNS lymphoma: the next step.
    Abrey LE; Yahalom J; DeAngelis LM
    J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
    Lebel E; Goldschmidt N; Siegal T; Lossos A; Rosenberg S; Makranz C; Linetski E; Gatt ME; Gural A; Saban R; Lavie D; Vainstein V; Zimran E; Avni B; Grisaro S; Shaulov A; Nachmias B
    Leuk Lymphoma; 2022 Sep; 63(9):2102-2108. PubMed ID: 35491706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma.
    Masaki Y; Miki M; Sun Y; Nakamura T; Iwao H; Nakajima A; Kurose N; Sakai T; Jin ZX; Sawaki T; Kawanami T; Fujita Y; Tanaka M; Fukushima T; Hirose Y; Umehara H
    Int J Hematol; 2011 Jun; 93(6):720-726. PubMed ID: 21573892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.
    Kim YR; Kim SH; Chang JH; Suh CO; Kim SJ; Kim Y; Hwang DY; Jang JE; Hyun SY; Cheong JW; Min YH; Kim JS
    Ann Hematol; 2014 Feb; 93(2):211-9. PubMed ID: 23903866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing second line and beyond therapies for primary central nervous system lymphomas.
    Primeaux B; Luo C; Yeung EK; Linger C; Chen S; Do B
    Hematol Oncol; 2024 Nov; 42(6):e3313. PubMed ID: 39340121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
    Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
    Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
    Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.